Serono says Raptiva provides 'significant' improvement in plaque psoriasis

By Elaine Rigoli

Tampa, Fla., June 22 - Serono said 12-week data demonstrated that Raptiva produced significant clinical improvements and was generally well-tolerated among patients refractory, intolerant or contraindicated to systemic therapies as well as in the total population of patients with moderate-to-severe plaque psoriasis.

Following the 12-week treatment, Raptiva demonstrated a favorable safety profile and was clinically superior to a placebo in showing a statistically significantly higher PASI 75 rate, the primary efficacy endpoint of the study.

Clear is a multinational, randomized, double-blind, placebo-controlled, parallel-group trial demonstrating the efficacy of a biological therapy in an international patient population, where patients have previously failed to respond to other systemic therapies, or where these were inappropriate due to contraindications or intolerance.

Serono said Clear demonstrates that Raptiva is an effective therapy in moderate-to-severe plaque psoriasis patients regardless of previous systemic treatments.

Serono is a global biotechnology company with headquarters in Geneva, Switzerland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.